Business
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
NEW YORK & LYON, France, March 23, 2026--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 VALOR "Vaccine Against Lyme for Outdoor Recreationists" clinical trial (NCT05477524) of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 (LB6V, formerly known as VLA15) demonstrating:
About this update from Valneva Se
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":212,"url":"https://media.zenfs.com/en/business-wire.com/c102a8658015ffdc1b0351bcbf037a37"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CxD6OxVlcmCSZ0adn5NGiw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyNA--/https://media.zenfs.com/en/business-wire.com/c102a8658015ffdc1b0351bcbf037a37","width":480,"height":212}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above","length":140,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The investigational vaccine candidate was well tolerated with no safety concerns identified at time of analysis","length":111,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Overall, results strengthen confidence in the vaccine candidate and Pfizer is planning submissions to regulatory authorities","length":124,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":375,"olType":false},{"type":"text","content":"NEW YORK & LYON, France, March 23, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 VALOR "Vaccine Against Lyme for Outdoor Recreationists" clinical trial (NCT05477524) of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 (LB6V, formerly known as VLA15) demonstrating:","length":413,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In the pre-specified analyses:","length":30,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Efficacy of 73.2% from 28 days post-dose 4 (season 2) in reducing the rate of confirmed Lyme disease cases compared to the placebo arm (95% CI 15.8, 93.5)","length":154,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Efficacy of 74.8% from 1-day post-dose 4 (season 2) in reducing the rate of confirmed Lyme disease cases compared to the placebo arm (95% CI 21.7, 93.9)","length":152,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":306,"olType":false}]}],"tagName":"ul","bulletedList":true,"length...